Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Medical School

University of Virginia School of Medicine

1991, Charlottesville, VA

Internship

General Surgery

Georgetown University Hospital

Washington, DC

Residency

Surgery

Georgetown University Hospital

Washington, DC

Residency

Radiation Oncology

University of Pennsylvania School of Medicine

1995, Philadelphia, PA

Fellowship

Brachytherapy

Memorial Sloan Kettering Cancer Center

1996, New York, NY

Certifications

  • American Board of Radiology (Radiation Oncology)

Professional History

Phillip Devlin, MD, FACR is Associate Professor of Radiation Oncology at Harvard Medical School and Chief of the Division of Brachytherapy in the Department of Radiation Oncology at the Dana-Farber/Brigham and Women’s Cancer Center. He earned his medical degree at the University of Virginia School of Medicine in 1991 and completed his residency in Radiation Oncology at the University of Pennsylvania in 1995, followed by a specialized fellowship in brachytherapy at Memorial Sloan-Kettering Cancer Center in 1996. Dr. Devlin joined the staff of Dana-Farber in 1997.In addition to lecturing extensively both nationally and internationally, Dr. Devlin established and directs the Harvard Medical School Annual Brachytherapy Review Course, has more than 50 published manuscripts and book chapters and is editor of the Lippincott, Williams and Wilkins’ text, Brachytherapy: Applications and Techniques. Dr. Devlin is currently on the Executive Committees of both the American Society for Radiation Oncology (ASTRO) and the Massachusetts Radiological Society. In 2008 he was named a Fellow of the American College of Radiology (FACR), and he is currently leading two funded studies as part of the ACR’s Quality Research in Radiation Oncology (QRRO) project.

Publications

  1. Refractory cutaneous Langerhans cell histiocytosis of the vulva treated with high-dose-rate surface applicator brachytherapy. Leuk Lymphoma. 2025 Apr 23; 1-4. View Abstract

  2. Skin marker for MR-only surface high-dose-rate brachytherapy. J Contemp Brachytherapy. 2025 Feb; 17(1):43-53. View Abstract

  3. RapidBrachyIVBT: A dosimetry software for patient-specific intravascular brachytherapy dose calculations on optical coherence tomography images. Med Phys. 2025 Feb; 52(2):1256-1267. View Abstract

  4. Feasibility and clinical implementation of MRI-guided surface brachytherapy. J Contemp Brachytherapy. 2024 Feb; 16(1):48-56. View Abstract

  5. Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides. J Invest Dermatol. 2024 03; 144(3):621-632.e1. View Abstract

  6. Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases. JAAD Case Rep. 2023 Jan; 31:62-65. View Abstract

  7. Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 08; 173:32-40. View Abstract

  8. Brachytherapy as Salvage Treatment for Meningioma With Malignant Progression After Exhausting Other Treatment Options: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown). 2022 05 01; 22(5):e215. View Abstract

  9. ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy. Am J Clin Oncol. 2022 06 01; 45(6):243-248. View Abstract

  10. Salvage brachytherapy for multiply recurrent metastatic brain tumors: A matched case analysis. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac039. View Abstract

  11. The Essential Anthony. Int J Radiat Oncol Biol Phys. 2021 Dec 01; 111(5):1123-1124. View Abstract

  12. Feasibility of magnetic resonance-only high-dose-rate surface brachytherapy for clinical application. Med Phys. 2021 Nov; 48(11):7313-7322. View Abstract

  13. Acute and late complications and toxicities of skin brachytherapy. Brachytherapy. 2021 Sep-Oct; 20(5):1041-1052. View Abstract

  14. Selection criteria for high-dose-rate surface brachytherapy and electron beam therapy in cutaneous oncology. J Contemp Brachytherapy. 2021 Apr; 13(2):195-204. View Abstract

  15. Clinical outcomes following high-dose-rate surface applicator brachytherapy for angiosarcoma of scalp and face. J Contemp Brachytherapy. 2021 Apr; 13(2):172-178. View Abstract

  16. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. Brachytherapy. 2021 May-Jun; 20(3):497-511. View Abstract

  17. Pediatric primary cutaneous anaplastic large cell lymphoma treated with brachytherapy. Pediatr Dermatol. 2021 May; 38(3):712-713. View Abstract

  18. Recalcitrant extramammary Paget's disease treated successfully with high-dose-rate brachytherapy: A case series and review of the literature. Dermatol Ther. 2021 03; 34(2):e14755. View Abstract

  19. Angiosarcoma of the Scalp and Face: A Dosimetric Comparison of HDR Surface Applicator Brachytherapy and VMAT. Sarcoma. 2020; 2020:7615248. View Abstract

  20. Multilingual Analysis of the Quality and Readability of Online Health Information on the Adverse Effects of Breast Cancer Treatments. JAMA Surg. 2020 08 01; 155(8):781-784. View Abstract

  21. Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer. 2020 09 01; 126(17):3900-3906. View Abstract

  22. Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. J Am Acad Dermatol. 2021 Jan; 84(1):168-172. View Abstract

  23. Combined interstitial and surface high-dose-rate brachytherapy treatment of squamous cell carcinoma of the hand. J Contemp Brachytherapy. 2020 Feb; 12(1):48-52. View Abstract

  24. In Reply to the American Academy of Dermatology Letter Regarding: Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: An American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020 May - Jun; 10(3):211-212. View Abstract

  25. Development and clinical implementation of semi-automated treatment planning including 3D printable applicator holders in complex skin brachytherapy. Med Phys. 2020 Mar; 47(3):869-879. View Abstract

  26. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020 Jan - Feb; 10(1):8-20. View Abstract

  27. Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study. J Neurooncol. 2020 Jan; 146(1):111-120. View Abstract

  28. Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res. 2020 01 15; 26(2):408-418. View Abstract

  29. Modern Brachytherapy. Hematol Oncol Clin North Am. 2019 12; 33(6):1011-1025. View Abstract

  30. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol. 2019 07; 42(7):564-572. View Abstract

  31. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. View Abstract

  32. High-throughput sequencing of the T cell receptor ß gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med. 2018 05 09; 10(440). View Abstract

  33. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20. View Abstract

  34. American College of Radiology-American Brachytherapy Society practice parameter for electronically generated low-energy radiation sources. Brachytherapy. 2017 Nov - Dec; 16(6):1083-1090. View Abstract

  35. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58. View Abstract

  36. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911. View Abstract

  37. Dose comparison between TG-43-based calculations and radiochromic film measurements of the Freiburg flap applicator used for high-dose-rate brachytherapy treatments of skin lesions. Brachytherapy. 2017 Sep - Oct; 16(5):1065-1072. View Abstract

  38. Custom-made micro applicators for high-dose-rate brachytherapy treatment of chronic psoriasis. J Contemp Brachytherapy. 2017 Jun; 9(3):263-269. View Abstract

  39. Usefulness of Intracoronary Brachytherapy for Patients With Resistant Drug-Eluting Stent Restenosis. Am J Cardiol. 2017 Aug 01; 120(3):369-373. View Abstract

  40. Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau. JAMA Dermatol. 2017 04 01; 153(4):331-332. View Abstract

  41. The value of systematic contouring of the bowel for treatment plan optimization in image-guided cervical cancer high-dose-rate brachytherapy. Brachytherapy. 2017 May - Jun; 16(3):579-585. View Abstract

  42. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis. J Vasc Surg. 2017 03; 65(3):734-743. View Abstract

  43. Skin surface brachytherapy: A survey of contemporary practice patterns. Brachytherapy. 2017 Jan - Feb; 16(1):223-229. View Abstract

  44. Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience. Gynecol Oncol. 2016 Dec; 143(3):545-551. View Abstract

  45. Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer. J Contemp Brachytherapy. 2016 Aug; 8(4):319-25. View Abstract

  46. Successful use of brachytherapy for a severe hidradenitis suppurativa variant. Dermatol Ther. 2016 Nov; 29(6):455-458. View Abstract

  47. WE-DE-201-11: Sensitivity and Specificity of Verification Methods Based On Total Reference Air Kerma (TRAK) Or On User Provided Dose Points for Graphically Planned Skin HDR Brachytherapy. Med Phys. 2016 Jun; 43(6):3810-3811. View Abstract

  48. SU-G-201-04: Can the Dynamic Library of Flap Applicators Replace Treatment Planning in Surface Brachytherapy? Med Phys. 2016 Jun; 43(6):3623. View Abstract

  49. Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis. Clin Exp Dermatol. 2016 Jul; 41(5):498-501. View Abstract

  50. Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy. JAMA Dermatol. 2015 Dec 01; 151(12):1354-1357. View Abstract

  51. American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy. 2016 Jan-Feb; 15(1):1-11. View Abstract

  52. Brachytherapy in the treatment of recurrent aggressive falcine meningiomas. J Neurooncol. 2015 Sep; 124(3):515-22. View Abstract

  53. SU-E-T-783: Using Matrixx to Determine Transit Dose Contribution Over Clinically Useful Limits of HDR Source Activity. Med Phys. 2015 Jun; 42(6):3517. View Abstract

  54. SU-E-T-413: Examining Acquisition Rate for Using MatriXX Ion Chamber Array to Measure HDR Brachytherapy Treatments. Med Phys. 2015 Jun; 42(6):3429. View Abstract

  55. SU-E-T-301: Dosimetric Comparison Between Adaptive and Rectilinear Template-Based Prostate Seed Implants. Med Phys. 2015 Jun; 42(6):3402. View Abstract

  56. SU-E-T-165: Characterization of Dose Distributions in High-Dose-Rate Surface Brachytherapy. Med Phys. 2015 Jun; 42(6):3369. View Abstract

  57. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. View Abstract

  58. High-dose-rate Interstitial Brachytherapy Boost with a Pedicled Latissimus Dorsi Myocutaneous Flap for Myxofibrosarcoma of the Arm. Plast Reconstr Surg Glob Open. 2014 Oct; 2(10):e229. View Abstract

  59. Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol. 2015 May; 22(5):1455-63. View Abstract

  60. Independent brachytherapy plan verification software: improving efficacy and efficiency. Radiother Oncol. 2014 Dec; 113(3):420-4. View Abstract

  61. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014 Sep 09; 9:200. View Abstract

  62. WE-A-17A-03: Catheter Digitization in High-Dose-Rate Brachytherapy with the Assistance of An Electromagnetic (EM) Tracking System. Med Phys. 2014 Jun; 41(6):487-488. View Abstract

  63. SU-E-T-362: Automatic Catheter Reconstruction of Flap Applicators in HDR Surface Brachytherapy. Med Phys. 2014 Jun; 41(6):308. View Abstract

  64. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9. View Abstract

  65. PSA screening: the case in favor. Oncology (Williston Park). 2013 Oct; 27(10):980, 982. View Abstract

  66. Equivalent uniform dose for accelerated partial breast irradiation using the MammoSite applicator. Radiother Oncol. 2013 Aug; 108(2):232-5. View Abstract

  67. Palliative treatment for in-transit cutaneous metastases of Merkel cell carcinoma using surface-mold computer-optimized high-dose-rate brachytherapy. Cancer J. 2013 Jul-Aug; 19(4):283-7. View Abstract

  68. Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013 Jul; 69(1):61-5. View Abstract

  69. American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy. Brachytherapy. 2013 May-Jun; 12(3):179-90. View Abstract

  70. Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013 Jul; 20(7):2140-7. View Abstract

  71. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol. 2013 May; 20(5):1494-9. View Abstract

  72. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):355-62. View Abstract

  73. Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy. Brachytherapy. 2013 Jan-Feb; 12(1):19-24. View Abstract

  74. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83. View Abstract

  75. Variability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):249. View Abstract

  76. Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol. 2011 Jul; 147(7):870-2. View Abstract

  77. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8. View Abstract

  78. Treatment of cutaneous metastases of Merkel cell carcinoma with surface-mold computer-optimized high-dose-rate brachytherapy. J Clin Oncol. 2010 Sep 20; 28(27):e464-6. View Abstract

  79. Mammographic appearance following accelerated partial breast irradiation by using MammoSite brachytherapy. Radiology. 2010 May; 255(2):362-8. View Abstract

  80. Partial breast irradiation: a review of techniques and indications. Br J Radiol. 2010 May; 83(989):369-78. View Abstract

  81. Counterpoint: the dose rate argument--Does size matter after all? Brachytherapy. 2009 Jul-Sep; 8(3):273-5. View Abstract

  82. Rebuttal to Drs. Davidson, Hendry, and West: once burned, twice shy? Brachytherapy. 2009 Jul-Sep; 8(3):277. View Abstract

  83. Permanent iodine-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1114-20. View Abstract

  84. Radiation lobectomy-a minimally invasive treatment model for liver cancer: case report. J Vasc Interv Radiol. 2009 May; 20(5):664-9. View Abstract

  85. Intraoperative seed placement for thoracic malignancy-A review of technique, indications, and published literature. Brachytherapy. 2009 Jan-Mar; 8(1):63-9. View Abstract

  86. Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields. Radiat Oncol. 2008 Nov 19; 3:39. View Abstract

  87. Intersociety Radiation Oncology Summit-SCOPE II. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):323-6. View Abstract

  88. Palonosetron--a single-dose antiemetic adjunct for hepatic artery radioembolization: a feasibility study. Cardiovasc Intervent Radiol. 2009 Jan; 32(1):47-51. View Abstract

  89. Brachytherapy partial breast irradiation: analyzing effect of source configurations on dose metrics relevant to toxicity. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):940-4. View Abstract

  90. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand. 2008 Apr; 117(4):271-6. View Abstract

  91. Permanent planar iodine-125 implants: the dosimetric effect of geometric parameters for idealized source configurations. Int J Radiat Oncol Biol Phys. 2007 Nov 15; 69(4):1310-5. View Abstract

  92. Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate. Urol Oncol. 2008 Mar-Apr; 26(2):147-52. View Abstract

  93. Inherent change in MammoSite applicator three-dimensional geometry over time. Radiat Oncol. 2007 Sep 24; 2:37. View Abstract

  94. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy. 2007 Jan-Mar; 6(1):34-7. View Abstract

  95. Severe toxicity after permanent radioactive seed implantation for mediastinal carcinoid tumors. Brachytherapy. 2007 Jan-Mar; 6(1):58-61. View Abstract

  96. Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):91-9. View Abstract

  97. The history of the smallpox vaccine. J Infect. 2006 May; 52(5):329-34. View Abstract

  98. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005 Jul 07; 3:27. View Abstract

  99. Definitive radiotherapy with interstitial implant boost for squamous cell carcinoma of the tongue base. Head Neck. 2005 May; 27(5):353-61. View Abstract

  100. CT computer-optimized high-dose-rate brachytherapy with surface applicator technique for scar boost radiation after breast reconstruction surgery. Brachytherapy. 2005; 4(3):224-9. View Abstract

  101. Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up. Am J Clin Oncol. 2004 Aug; 27(4):369-75. View Abstract

  102. Dosimetric consequences of manual pullback procedure for coronary artery radiotherapy with 90Sr/90Y beta-source. Brachytherapy. 2004; 3(4):215-21. View Abstract

  103. GAF film dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train. Med Phys. 2003 Jun; 30(6):1004-12. View Abstract

  104. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400. View Abstract

  105. An Internet-ready database for prospective randomized clinical trials of high-dose-rate brachytherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2002 May 01; 53(1):104-15. View Abstract

  106. Brachytherapy for soft tissue sarcomas. Cancer Treat Res. 1997; 91:107-28. View Abstract

  107. Diversity and organization of human T cell receptor delta variable gene segments. J Exp Med. 1989 Jan 01; 169(1):41-57. View Abstract

  108. Extensive junctional diversity of rearranged human T cell receptor delta genes. Science. 1988 Jun 10; 240(4858):1541-4. View Abstract
BESbswy